Ocugen, Inc.
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, we are advancing vaccine research in the fight against COVID-19, and our work in cell therapy is aimed at orthopedic disease for which no effective treatment options currently exist.
NEWS
This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
Bharat will conduct Phase IV studies to check real-world efficacy against the virus, while Ocugen says Covaxin will be a valuable tool in helping to end the COVID-19 pandemic.
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
A new study published online has provided some hope for the citizens in India, with researchers suggesting that the Covaxin vaccine, developed by Bharat Biotech and Pennsylvania-based Ocugen, could neutralize the SARS-CoV-2 variant leading the second wave in the country.
Ocugen’s plan to bring a COVID-19 vaccine developed by India-based Bharat Biotech later this year remains on track following an interim analysis of Phase III data that shows the vaccine demonstrated a 78% efficacy against mild to moderate infection and 100% efficacy against severe COVID-19.
JOBS
IN THE PRESS